GLP-1 and GIP

Phase 1Small molecule

TThe University of Texas Health Science Center at San Antonio

GLP-1 and GIP is one of 20 small molecule programs targeting Insulin Secretion. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin SecretionRecruiting

Insulin SecretionPhase 1

Recruiting

Competition

Competitive Landscape

20 competitors in Insulin Secretion

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

1 2

Precose

Bayer

Approved

1 3

Farxiga

AstraZeneca

Approved

1 4

Glucophage

EMD Serono

Approved

3 5

Prograf

VVeloxis Pharmaceuticals

Approved

1 6

Decadron

AAspen Global Incorporated

Approved

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 8

Starlix

Novartis

Approved

1 9

Exendin-(9-39)

EEiger BioPharmaceuticals

Phase 3

3 10

Calan

VVal Adams

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Insulin Secretion

NCT00992901

Clinical

Trials by Indication[1]

Insulin Secretion1 trial

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00992901·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GLP-1 and GIP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 and GIP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1 and GIP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center at San Antonio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe University of Texas Health Science Center at San Antonio

GLP-1 and GIP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Insulin Secretion1 trial

References

Drug Info

Quick Facts

Related News